These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 5447481)

  • 41. In vitro drug release rate as a standard requirement.
    Láng B
    Pharmazie; 1971 Nov; 26(11):661-4. PubMed ID: 5154319
    [No Abstract]   [Full Text] [Related]  

  • 42. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.
    ; ;
    Stat Med; 2006 May; 25(10):1628-38. PubMed ID: 16639773
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparability is not just analytical equivalence.
    Lubiniecki AS; Marcia Federici M
    Biologicals; 2006 Mar; 34(1):45-7. PubMed ID: 16330221
    [No Abstract]   [Full Text] [Related]  

  • 44. New York State and drug lists: a history of confusion.
    Stetler CJ
    Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract]   [Full Text] [Related]  

  • 45. Uptake of biosimilar therapies--opportunities and obstacles. Commentary.
    Goldsmith D
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v1-3. PubMed ID: 16959788
    [No Abstract]   [Full Text] [Related]  

  • 46. Quality assurance and pharmacological equivalency.
    Pflag SC
    Mil Med; 1968 Jun; 133(6):486-90. PubMed ID: 4988430
    [No Abstract]   [Full Text] [Related]  

  • 47. DHSS to go ahead with restrictive list. Nurses strongly against limited drugs list plan.
    Sargent M
    Nurs Stand (1984); 1985 Jan; (381):2. PubMed ID: 3844078
    [No Abstract]   [Full Text] [Related]  

  • 48. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?
    Furberg CD; Psaty BM
    Circulation; 2003 Nov; 108(21):2608-10. PubMed ID: 14638524
    [No Abstract]   [Full Text] [Related]  

  • 49. A time to speak out on bioequivalence and therapeutic equivalence.
    Dettelbach HR
    J Clin Pharmacol; 1986; 26(5):307-8. PubMed ID: 2871052
    [No Abstract]   [Full Text] [Related]  

  • 50. Drugs and the elderly. Product-to-product variability.
    Todd B
    Geriatr Nurs; 1985; 6(1):57-8. PubMed ID: 3843831
    [No Abstract]   [Full Text] [Related]  

  • 51. Generics in trouble.
    Lee NC
    S Afr Med J; 1987 Jun; 71(11):680. PubMed ID: 3589859
    [No Abstract]   [Full Text] [Related]  

  • 52. [For the sake of quality].
    Pijpers A
    Tijdschr Diergeneeskd; 1994 Aug; 119(14-15):432-8. PubMed ID: 8066580
    [No Abstract]   [Full Text] [Related]  

  • 53. [Biopharmaceutics, biodisposibility, bioequivalency].
    Cingolani E
    Ann Ist Super Sanita; 1982; 18(3):531-2. PubMed ID: 7187840
    [No Abstract]   [Full Text] [Related]  

  • 54. Biopharmaceutics and drug standards.
    Feldmann EG
    Am J Hosp Pharm; 1968 Mar; 25(3):111-9. PubMed ID: 5658858
    [No Abstract]   [Full Text] [Related]  

  • 55. Incidence of substandard drugs in developing countries.
    Afu S
    Trop Med Int Health; 1999 Jan; 4(1):73. PubMed ID: 10203177
    [No Abstract]   [Full Text] [Related]  

  • 56. Canadian experience.
    Cook D
    Pharmacology; 1972; 8(1):190-8. PubMed ID: 4644648
    [No Abstract]   [Full Text] [Related]  

  • 57. The profession of medicine.
    Azarnoff DL
    Pharmacology; 1972; 8(1):211-2. PubMed ID: 4644652
    [No Abstract]   [Full Text] [Related]  

  • 58. Generic drugs.
    Med Lett Drugs Ther; 1999 May; 41(1053):47-8. PubMed ID: 10368699
    [No Abstract]   [Full Text] [Related]  

  • 59. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees.
    Brown D; Volkers P; Day S
    Stat Med; 2006 May; 25(10):1623-7. PubMed ID: 16639776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cmax/AUC, a commentary.
    Tozer TN; Hauck WW
    Pharm Res; 1997 Aug; 14(8):967-8. PubMed ID: 9279874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.